TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
The purpose of this study is to determine whether AMG 386 or AMG 386 Placebo in combination with Paclitaxel and Carboplatin are effective in the treatment of ovarian cancer.
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cancer
DRUG: AMG 386|DRUG: Paclitaxel|DRUG: AMG 386 Placebo|DRUG: Carboplatin
Progression free survival, 3 years
Overall survival (OS), 5 years|Incidence of adverse events and significant laboratory abnormalities, 4 years|Pharmacokinetics of AMG 386 (Cmax and Cmin), pre-dose weeks 1, 7, 10, 19 and within 10 minutes post dose week 1, 7, 1 year|Incidence of anti-AMG 386 antibody formation, pre-dose weeks 1, 10, 19, 4 years|Patient reported ovarian cancer-specific symptoms and health related quality of life, 4 years|Patient reported status as measured by the EuroQOL (EQ-5D), 4 years|AMG 386 exposure-response relationships for PFS and OS, 4 years|Correlation of serum biomarkers with measures of response, 4 years
The purpose of this study is to determine whether AMG 386 or AMG 386 Placebo in combination with Paclitaxel and Carboplatin are effective in the treatment of ovarian cancer.